CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
Limitations of Use:
CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.
A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers.
Source: the FDA label for Cerdelga (Genzyme Corporation), March 3, 2024. Full label on DailyMed
Good to know
“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/cerdelga/